cpo102
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2022 (NCT05043987)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Claudin-18ADCC
CLDN18 adcc
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05043987 | Phase 1 | Feb 15, 2022 | Shijiazhuang Pharma Group (CSPC), Yiling Pharmaceutical Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 0 | 1 | 2022 |
| Yiling Pharmaceutical Inc. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1